ImmuCell Corporation (ICCC)
ImmuCell Statistics
Share Statistics
ImmuCell has 8.98M shares outstanding. The number of shares has increased by 14.08% in one year.
| Shares Outstanding | 8.98M |
| Shares Change (YoY) | 14.08% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 14.76% |
| Shares Floating | 5.79M |
| Failed to Deliver (FTD) Shares | 2K |
| FTD / Avg. Volume | 11.57% |
Short Selling Information
The latest short interest is 13.16K, so 0.15% of the outstanding shares have been sold short.
| Short Interest | 13.16K |
| Short % of Shares Out | 0.15% |
| Short % of Float | 0.18% |
| Short Ratio (days to cover) | 1.28 |
Valuation Ratios
The PE ratio is -19.5 and the forward PE ratio is -50. ImmuCell's PEG ratio is 0.3.
| PE Ratio | -19.5 |
| Forward PE | -50 |
| PS Ratio | 1.59 |
| Forward PS | 2.6 |
| PB Ratio | 1.59 |
| P/FCF Ratio | -390.09 |
| PEG Ratio | 0.3 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ImmuCell.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0, with a Debt / Equity ratio of 0.57.
| Current Ratio | 0 |
| Quick Ratio | 0 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 14.46 |
| Debt / FCF | -140.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $383.96K |
| Profits Per Employee | $-31.26K |
| Employee Count | 69 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 10K |
| Effective Tax Rate | -0.47% |
Stock Price Statistics
The stock price has increased by 9.56% in the last 52 weeks. The beta is 0.39, so ImmuCell's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | 9.56% |
| 50-Day Moving Average | 5.1 |
| 200-Day Moving Average | 4.38 |
| Relative Strength Index (RSI) | 59.13 |
| Average Volume (20 Days) | 17.29K |
Income Statement
In the last 12 months, ImmuCell had revenue of 26.49M and earned -2.16M in profits. Earnings per share was -0.26.
| Revenue | 26.49M |
| Gross Profit | 7.94M |
| Operating Income | -1.64M |
| Net Income | -2.16M |
| EBITDA | 1.04M |
| EBIT | -1.64M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
The company has 3.76M in cash and 15.1M in debt, giving a net cash position of -11.34M.
| Cash & Cash Equivalents | 3.76M |
| Total Debt | 15.1M |
| Net Cash | -11.34M |
| Retained Earnings | -14.16M |
| Total Assets | 45.1M |
| Working Capital | 10.63M |
Cash Flow
In the last 12 months, operating cash flow was 357.9K and capital expenditures -465.73K, giving a free cash flow of -107.82K.
| Operating Cash Flow | 357.9K |
| Capital Expenditures | -465.73K |
| Free Cash Flow | -107.82K |
| FCF Per Share | -0.01 |
Margins
Gross margin is 29.97%, with operating and profit margins of -6.19% and -8.14%.
| Gross Margin | 29.97% |
| Operating Margin | -6.19% |
| Pretax Margin | -8.1% |
| Profit Margin | -8.14% |
| EBITDA Margin | 3.94% |
| EBIT Margin | -6.19% |
| FCF Margin | -0.41% |
Dividends & Yields
ICCC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ICCC.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 25, 1990. It was a backward split with a ratio of 1:100.
| Last Split Date | Jul 25, 1990 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -39.66 |
| Piotroski F-Score | 6 |